delstrigo
merck sharp & dohme b.v. - doravirine, áhrif, nýrnastarfsemi disoproxil fúmarat - hiv sýkingar - veirueyðandi lyf til meðferðar á hiv sýkingum, samsetningum - delstrigo er ætlað fyrir meðferð fullorðnir með hiv 1 án fortíðinni eða sannanir á andstöðu við nnrti flokki, áhrif, eða nýrnastarfsemi. delstrigo is also indicated for the treatment of adolescents aged 12 years and older weighing at least 35 kg who are infected with hiv-1 without past or present evidence of resistance to the nnrti class, lamivudine, or tenofovir and who have experienced toxicities which preclude the use of other regimens that do not contain tenofovir disoproxil.
pifeltro
merck sharp & dohme b.v. - doravirine - hiv sýkingar - veirueyðandi lyf til almennrar notkunar - pifeltro is indicated, in combination with other antiretroviral medicinal products, for the treatment of adults, and adolescents aged 12 years and older weighing at least 35 kg infected with hiv 1 without past or present evidence of resistance to the nnrti class.
diovan mixtúra, lausn 3 mg/ml
novartis healthcare a/s - valsartanum inn - mixtúra, lausn - 3 mg/ml
kairasec tafla 8 mg
medical valley invest ab - candesartanum cílexetíl - tafla - 8 mg
kairasec tafla 16 mg
medical valley invest ab - candesartanum cílexetíl - tafla - 16 mg
candpress tafla 16 mg
teva b.v.* - candesartanum cílexetíl - tafla - 16 mg
candpress tafla 8 mg
teva b.v.* - candesartanum cílexetíl - tafla - 8 mg
cloxabix hart hylki 100 mg
williams & halls ehf - celecoxibum inn - hart hylki - 100 mg
cloxabix hart hylki 200 mg
williams & halls ehf - celecoxibum inn - hart hylki - 200 mg
kairasec tafla 32 mg
medical valley invest ab - candesartanum cílexetíl - tafla - 32 mg